GlassScriptPhysician profile
Danielle R Lazzara
NPI 1912351347
$7,273.74
in general payments reported to CMS, 2019-2025
28 companies · $2,559 in 2025
The $2,559 reported for 2025 was more than what 92% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $92.47 · 2021: $694 · 2022: $1,043 · 2023: $985 · 2024: $782 · 2025: $2,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,320 · Food and Beverage: $2,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,320.00 |
| Food and Beverage | $2,006.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $2,697.45 | 2023-2025 | Affinity, Puraply, Cygnus Dual |
| Abbvie INC. | $1,329.17 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $611.71 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $335.00 | 2021-2025 | |
| Leo Pharma INC. | $297.60 | 2022-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $291.88 | 2021-2024 | |
| Galderma Laboratories, L.P. | $238.67 | 2019 | |
| Janssen Biotech, INC. | $193.02 | 2021-2024 | Tremfya, Remicade, Simponi Aria |
| Incyte Corporation | $181.14 | 2022-2023 | Opzelura |
| Sun Pharmaceutical Industries INC. | $166.10 | 2021-2023 | Ilumya, Winlevi, Absorica Ld |
| Allergan, INC. | $149.63 | 2019 | |
| Amgen INC. | $113.15 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $107.24 | 2019 | |
| Ucb, INC. | $93.08 | 2022-2024 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $77.98 | 2022-2025 | Sotyktu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $50.89 | 2020 | |
| Revance Therapeutics, INC. | $50.41 | 2025 | Daxxify |
| Lilly USA, LLC | $46.84 | 2023-2024 | Taltz, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.07 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.99 | 2021-2022 | |
| Dermavant Sciences, INC. | $39.26 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $23.42 | 2023 | |
| Epi Health, LLC | $19.53 | 2022 | |
| Smith+Nephew, INC. | $19.01 | 2019 | |
| Merck Sharp & Dohme LLC | $17.36 | 2019 | |
| Fidia Pharma USA INC. | $15.00 | 2025 | Triluron, Hymovis |
| Surgenex LLC | $14.98 | 2025 | Ardeograft, Surgraft, Surmatrix |
| Biofrontera INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Lazzara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.